Neutralization of Type I IFN signaling with an IFNAR blocking antibody (Fig. 6A) resulted in 100% of IFNAR-treated mice being nonresponsive to SCRT (Fig. 6B) with larger tumor burden upon sacrifice on day twenty compared to the IgG-treated controls (Fig. 6C, D). This evidence concerns the gene IFNAR1 and neoplasm.